High Pretreatment Serum PD-L1 Levels Are Associated with Muscle Invasion and Shorter Survival in Upper Tract Urothelial Carcinoma

• Published in: Biomedicines 2022-10, Vol.10 (10), p.2560
• Main Authors: Széles, Ádám, Kovács, Petra Terézia, Csizmarik, Anita, Váradi, Melinda, Riesz, Péter, Fazekas, Tamás, Váncsa, Szilárd, Hegyi, Péter, Oláh, Csilla, Tschirdewahn, Stephan, Darr, Christopher, Krafft, Ulrich, Grünwald, Viktor, Hadaschik, Boris, Horváth, Orsolya, Nyirády, Péter, Szarvas, Tibor
• Format: Article
• Language: English
• Subjects: biomarker; Biopsy; Bladder cancer; Cancer therapies; Chemotherapy; Decision making; Immune checkpoint inhibitors; Localization; Lymphatic system; Medical prognosis; Metastases; Metastasis; Patients; PD-L1 protein; Physiological aspects; prognosis; soluble programmed death ligand-1; sPD-L1; Survival; Therapeutic targets; Tumors; upper tract urothelial carcinoma; Urogenital system; Urothelial cancer; Urothelial carcinoma; UTUC
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines10102560

Programmed death ligand-1 (PD-L1) is an immune checkpoint molecule and a widely used therapeutic target in urothelial cancer. Its circulating, soluble levels (sPD-L1) were recently suggested to be associated with the presence and prognosis of various malignancies but have not yet been investigated in upper tract urothelial carcinoma (UTUC). In this study, we assessed sPD-L1 levels in 97 prospectively collected serum samples from 61 UTUC patients who underwent radical nephroureterectomy (RNU), chemotherapy (CTX), or immune checkpoint inhibitor (ICI) therapy. In addition to pretreatment samples, postoperative and on-treatment sPD-L1 levels were determined in some patients by using ELISA. In the RNU group, elevated preoperative sPD-L1 was associated with a higher tumor grade (p = 0.019), stage (p < 0.001) and the presence of metastasis (p = 0.002). High sPD-L1 levels were significantly associated with worse survival in both the RNU and CTX cohorts. sPD-L1 levels were significantly elevated in postoperative samples (p = 0.011), while they remained unchanged during CTX. Interestingly, ICI treatment caused a strong, 25-fold increase in sPD-L1 (p < 0.001). Our results suggest that elevated preoperative sPD-L1 level is a predictor of higher pathological tumor stage and worse survival in UTUC, which therefore may help to optimize therapeutic decision-making. The observed characteristic sPD-L1 flare during immune checkpoint inhibitor therapy may have clinical significance.